Table 1.
Baseline characteristics of patients admitted to the ICU with suspected septic shock (n = 508) and comparison between patients with early-confirmed septic shocks (EC-SS) and other patients (non EC-SS)
| All patients (n = 508) | EC-SS (n = 374) | Non EC-SS (n = 134) | P | |
|---|---|---|---|---|
| Age and gender | ||||
| Age, years | 68 (59–79) | 67 (58–80) | 68 (61–78) | 0.81 |
| Male gender | 297 (58) | 219 (59) | 78 (58) | >0.99 |
| Comorbidities | ||||
| Chronic respiratory disease | 21 (4) | 17 (5) | 4 (3) | 0.44 |
| Chronic heart failure | 34 (7) | 22 (6) | 12 (9) | 0.22 |
| Chronic kidney disease | 46 (9) | 33 (9) | 13 (10) | 0.76 |
| Cirrhosis | 49 (10) | 35 (9) | 14 (10) | 0.71 |
| Recent malignant hemopathy | 34 (7) | 27 (7) | 7 (5) | 0.43 |
| Recent cancer | 63 (12) | 43 (11) | 20 (15) | 0.30 |
| Diabetes mellitus | 132 (26) | 87 (23) | 45 (34) | 0.019 |
| HIV infection | 17 (3) | 11 (3) | 6 (4) | 0.40 |
| Obesity | 71 (14) | 54 (14) | 17 (13) | 0.62 |
| Cerebrovascular disease | 55 (11) | 37 (10) | 18 (13) | 0.26 |
| Immunosuppressive therapy | 54 (11) | 41 (11) | 13 (10) | 0.68 |
| Immunosuppression statusa | 132 (26) | 95 (25) | 37 (28) | 0.62 |
| No coexisting comorbid conditions | 154 (30) | 119 (32) | 35 (26) | 0.22 |
| Clinical data within 24 h of inclusion and antibiotic therapy | ||||
| Maximal temperature, °C | 38.2 (37.3–39.0) | 38.4 (37.4 − 39.1) | 37.9 (36.9 − 38.6) | <0.0001 |
| Minimal temperature, °C | 36.1 (35.2–37.0) | 36.2 (35.4–37.0) | 36.0 (34.6–36.8) | 0.006 |
| Glasgow Coma Scale | 14 (11–15) | 15 (12–15) | 13 (9–15) | 0.002 |
| SAPS2 | 58 (47–73) | 58 (45–72) | 59 (50–75) | 0.34 |
| Delay admission-inclusion, hours | 1 (0–6) | 2 (0–7) | 1 (0–4) | 0.33 |
| Delay inclusion -ATB1, hours | 0 (0–1) | 0 (0–1) | 0 (0–1) | 0.28 |
| Delay inclusion -ATB2, hours | 0 (0–2) | 0 (0–2) | 0 (0–2) | 0.59 |
| Number of ATB administered at 3 h | 2 (1–2) | 2 (1–2) | 2 (1–2) | 0.09 |
| Number of ATB administered at 24 h | 2 (2–3) | 2 (2–3) | 2 (1–3) | 0.050 |
| Biological data within 24 h of inclusion | ||||
| Leukocyte count, 103.mm−3 | 16.5 (9.9–24.6) | 17.1 (9.8–24.9) | 15.9 (9.9–23.0) | 0.62 |
| Platelets count, 103/mm−3 | 156 (85–243) | 156 (81–45) | 155 (92–236) | 0.72 |
| C-reactive protein, mg/Lb | 166 (87 − 265) | 178 (110 − 288) | 108 (48–179) | <0.0001 |
| Procalcitonin, ng/mLc | 7.6 (1.3–37.9) | 19.6 (3.7–56.5) | 1.6 (0.7–7.8) | <0.0001 |
| Serum urea, mmol/L | 14.0 (8.7–21.7) | 13.6 (8.7–20.0) | 16.0 (9.1–24.0) | 0.16 |
| Serum creatinine, μmoL/L | 187 (114–296) | 187 (115–275) | 198 (107–347) | 0.13 |
| Prothrombin time, % | 58 (41–72) | 58 (42–72) | 56 (38–72) | 0.72 |
| Arterial lactate, mmol/L | 3.5 (2.0–7.0) | 3.4 (2.0–6.1) | 3.6 (2.0–10.0) | 0.13 |
Categorical variables are expressed as number (%) and continuous variables as median (IQR 25–75). aImmunosuppression status includes patients with HIV or malignant hemopathy or recent cancer, or under immunosuppressive therapy. bValue available for 248 patients. cValue available for 128 patients. ATB antibiotic therapy, h hour, HIV human immunodeficiency virus, SAPS2 Simplified Acute Physiology Score, WBC white blood count